- $2.78m
- $5.40m
- CNY12.04m
- 17
- 60
- 17
- 22
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.21 | ||
| Price to Tang. Book | 1.78 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.64 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -82.1% | ||
| Return on Equity | -188.81% | ||
| Operating Margin | -825.97% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 10.25 | 10.85 | 20.51 | 17.99 | 12.04 | n/a | n/a | 16.2% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Fresh2 Group Ltd, formerly AnPac Bio-Medical Science Co Ltd, is a biotechnology company mainly engaged in early cancer screening and detection. The Company is engaged in marketing and selling multi-cancer screening and detection test that uses cancer differentiation analysis (CDA), technology and its cancer-detection device or CDA device. The Company's CDA technology also assists physicians in cancer diagnosis, prognosis and recurrence. The Company provides a platform on which it has developed cancer screening and detection test using its CDA technology, or CDA test, and its CDA device. Its CDA technology focuses on biophysical properties in human blood. The Company is also engaged in providing technical solution and outsourcing consulting service focusing on the digital, Internet, and Web3 transformation of start-ups and traditional enterprises.
Directors
- Chang Yu CHM (63)
- Herbert Yu CFD (64)
- Jinqiu Tang CFO (38)
- Weidong Dai CEX (60)
- Sunil Pandit CEX
- Xuedong Du VRD (41)
- Chao Feng DRC
- Feng Guo DRC (41)
- Sarah Yu DRC (32)
- Ren Luo IND (63)
- Jianhua Shao IND (61)
- Pu Xing IND (54)
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- January 28th, 2010
- Public Since
- January 30th, 2020
- No. of Employees
- 75
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 167,151,282
- Address
- 801 Bixing Street, Bihu County, Lishui, F4 323006
- Web
- http://www.anpac.cn/
- Phone
- +86 57820516666
- Auditors
- Friedman LLP
Upcoming Events for FRES
Similar to FRES
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Fresh2 share price?
As of Today at 20:45 UTC, shares in Fresh2 are trading at $0.32. This share price information is delayed by 15 minutes.
How has the Fresh2 share price performed this year?
Shares in Fresh2 last closed at $0.32 and the price had moved by -92.19% over the past 365 days. In terms of relative price strength the Fresh2 share price has underperformed the S&P500 Index by -93.79% over the past year.
What are the analyst and broker recommendations for Fresh2?
The overall consensus recommendation for Fresh2 is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Fresh2 dividend yield?
Fresh2 does not currently pay a dividend.
Does Fresh2 pay a dividend?
Fresh2 does not currently pay a dividend.
When does Fresh2 next pay dividends?
Fresh2 does not currently pay a dividend.
How do I buy Fresh2 shares?
To buy shares in Fresh2 you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Fresh2?
As of the previous close price of $0.32, shares in Fresh2 had a market capitalisation of $2.66m.
Where are Fresh2 shares listed?
Here are the trading details for Fresh2:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: FRES
What kind of share is Fresh2?
Based on an overall assessment of its quality, value and momentum Fresh2 is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Fresh2 share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Fresh2 share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Fresh2. Over the past six months, its share price has underperformed the S&P500 Index by -66.13%.
As of the last closing price of $0.32, shares in Fresh2 were trading -57.52% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Fresh2 PE Ratio?
The Fresh2 PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.32.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Fresh2?
Fresh2's management team is headed by:
- Chang Yu - CHM
- Herbert Yu - CFD
- Jinqiu Tang - CFO
- Weidong Dai - CEX
- Sunil Pandit - CEX
- Xuedong Du - VRD
- Chao Feng - DRC
- Feng Guo - DRC
- Sarah Yu - DRC
- Ren Luo - IND
- Jianhua Shao - IND
- Pu Xing - IND